Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity

NCT06215196 · Completed

Last updated 2026-05-28

This clinical trial tests whether adding a dietary fiber supplement called Soloways to the medication semaglutide helps reduce body weight in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 81 people

Who can join Ages 18–65 · all sexes

Timeline Started 2023-04 · est. completion 2023-08

Where 1 site · Russia

What this study is testing ClinicalTrials.gov NCT06215196 ↗

Description as written by the study sponsor.

This clinical trial investigated the combined effects of Semaglutide and a fiber supplement (glucomannan, inulin, psyllium) on weight loss in adults with overweight or obesity. Participants, aged 18-65 with a BMI ≥30 or ≥27 with comorbidities, were randomized into two groups: one receiving Semaglutide with active fiber supplements and the other with Semaglutide and placebo, over a 180-day period. Key endpoints included percentage change in body weight, BMI, body composition, safety, and appetite control, with a focus on evaluating the additive effects of dietary fibers in enhancing Semaglutide's efficacy.

Treatments tested

Fiber Supplement Group Dietary supplement

Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
placebo Other

Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.

Main thing measured	Percentage change in body weight from baseline
Sponsor	S.LAB (SOLOWAYS)
Conditions studied	Overweight and Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06215196 ↗